Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.

× No keyword cloud information.

3 in total

Review 1. Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors: R M Canetta; S K Carter
Journal: J Cancer Res Clin Oncol Date: 1984 Impact factor: 4.553

Review 2. The role of m⁶A, m⁵C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.

Authors: Paz Nombela; Borja Miguel-López; Sandra Blanco
Journal: Mol Cancer Date: 2021-01-18 Impact factor: 27.401

3. Inhibition of human dyskerin as a new approach to target ribosome biogenesis.

Authors: Laura Rocchi; Arménio J M Barbosa; Carmine Onofrillo; Alberto Del Rio; Lorenzo Montanaro
Journal: PLoS One Date: 2014-07-10 Impact factor: 3.240

3 in total

Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma.

Review 1. Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Review 2. The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.

3. Inhibition of human dyskerin as a new approach to target ribosome biogenesis.

Review 2. The role of m⁶A, m⁵C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.